Princess Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.11 M
- Company Age 42 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -14.96%
- Profit Growth -1.29%
- Ebitda -26.70%
- Net Worth 16.32%
- Total Assets 1.95%
About Princess Pharma
Princess Pharma Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 July 1982 and has a history of 42 years and six months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Princess Pharma Pvt Ltd. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Kiran Oza and Sandeep Oza serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24200MH1982PTC027898
- Company No.
027898
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 1982
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Princess Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiran Oza  | Director | 25-May-2004 | Current |
| Sandeep Oza | Director | 15-Apr-2005 | Current |
Financial Performance of Princess Pharma.
Princess Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.96% decrease. The company also saw a slight decrease in profitability, with a 1.29% decrease in profit. The company's net worth Soared by an impressive increase of 16.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Princess Pharma?
In 2023, Princess Pharma had a promoter holding of 99.55% and a public holding of 0.45%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Keminterpharm Spechem Resources Private LimitedKiran Oza is a mutual person
Kem Light Spechem Labs Private LimitedSandeep Oza is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Princess Pharma?
Unlock and access historical data on people associated with Princess Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Princess Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Princess Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.